<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2725">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808284</url>
  </required_header>
  <id_info>
    <org_study_id>PRJ2007</org_study_id>
    <nct_id>NCT04808284</nct_id>
  </id_info>
  <brief_title>Neuromodulation in COVID-19 Patients</brief_title>
  <official_title>Neuromodulation in COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>D'Or Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>D'Or Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is aimed at investigating the effects of transcranial direct current&#xD;
      stimulation (tDCS) on COVID-19 patients not admitted to the intensive care unit. The tDCS is&#xD;
      a non-invasive brain stimulation technique which applies a low intensity electrical current&#xD;
      in order to modulate neuronal activity. Patients included will be submitted to a single&#xD;
      session with active or sham tDCS, aiming to modulate prefrontal or supplementary motor area&#xD;
      (SMA). Evaluation protocol will be performed before and after stimulation to verify the&#xD;
      incidence of adverse events related to treatment and whether tDCS would affect measures of&#xD;
      executive functioning, mood, anxiety, autonomic response and motor function in COVID-19&#xD;
      patients. We hypothesize the neuromodulation would be a safety, promising treatment to reduce&#xD;
      possible impairments in COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events related to treatment (safety)</measure>
    <time_frame>post-treatment (up to one hour after the end of the treatment)</time_frame>
    <description>Safety as assessed by incidence of adverse events by type, frequency, severity, and causality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline autonomic response at the end of the treatment</measure>
    <time_frame>pre-treatment (baseline), post-treatment (up to one hour after the end of the treatment)</time_frame>
    <description>Heart rate variability (HRV) parameters change from pre-treatment to post-treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Trial Making Test (TMT) score at the end of the treatment</measure>
    <time_frame>pre-treatment (baseline), post-treatment (up to one hour after the end of the treatment)</time_frame>
    <description>Trial Making Test (TMT) score changes from pre-treatment to post-treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Digit span score at the end of the treatment</measure>
    <time_frame>pre-treatment (baseline), post-treatment (up to one hour after the end of the treatment)</time_frame>
    <description>Digit span score changes from pre-treatment to post-treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline balance parameters at the end of the treatment</measure>
    <time_frame>pre-treatment (baseline), post-treatment (up to one hour after the end of the treatment)</time_frame>
    <description>Balance parameters change from pre-treatment to post-treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline gait parameters at the end of the treatment</measure>
    <time_frame>pre-treatment (baseline), post-treatment (up to one hour after the end of the treatment)</time_frame>
    <description>Gait parameters change from pre-treatment to post-treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Functional Status Score for the intensive care unit (FSS-ICU) at the end of the treatment</measure>
    <time_frame>pre-treatment (baseline), post-treatment (up to one hour after the end of the treatment)</time_frame>
    <description>Functional Status Score for the intensive care unit (FSS-ICU) changes from pre-treatment to post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Functional Reach Test (FRT) distances at the end of the treatment</measure>
    <time_frame>pre-treatment (baseline), post-treatment (up to one hour after the end of the treatment)</time_frame>
    <description>Maximum distances reached by subject change from pre-treatment to post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Beck Depression Inventory-II (BDI-II) score at the end of the treatment</measure>
    <time_frame>pre-treatment (baseline), post-treatment (up to one hour after the end of the treatment)</time_frame>
    <description>Beck Depression Inventory-II (BDI-II) score changes from pre-treatment to post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Beck Anxiety Inventory (BAI) score at the end of the treatment</measure>
    <time_frame>pre-treatment (baseline), post-treatment (up to one hour after the end of the treatment)</time_frame>
    <description>Beck Anxiety Inventory (BAI) score changes from pre-treatment to post-treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>tDCS-SMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the supplementary motor area (SMA) for 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS- DLPFC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive a single tDCS session delivered at 2mA to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC) for 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS- SHAM</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants randomized to this arm will receive a single session of Sham tDCS for 30 minutes, delivered to supplementary motor area (SMA) or to the right (cathodal) and left (anodal) dorsolateral prefrontal cortex (DLPFC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct-current stimulation</intervention_name>
    <description>A single tDCS session will be delivered to the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be used, with one electrode (anode) placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region, according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.</description>
    <arm_group_label>tDCS-SMA</arm_group_label>
    <other_name>Active Transcranial direct-current stimulation</other_name>
    <other_name>tDCS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct-current stimulation</intervention_name>
    <description>A single tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) by a DC stimulator (NeuroConn, Germany). During stimulation, a pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed over F3 (anode) and F4 (cathode), according to the International 10-20 EEG system. Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 minutes current intensity will be ramp down for 30 seconds.</description>
    <arm_group_label>tDCS- DLPFC</arm_group_label>
    <other_name>Active Transcranial direct-current stimulation</other_name>
    <other_name>tDCS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Transcranial direct-current stimulation</intervention_name>
    <description>A single Sham-tDCS session will be applied bilaterally over the dorsolateral prefrontal cortex (DLPFC) or over the supplementary motor area (SMA) by a DC stimulator (NeuroConn, Germany). A pair of saline-soaked sponge electrodes (surface 35 cm²) will be placed according to the International 10-20 EEG system. For SMA , one electrode (anode) will be placed 1,8 cm forward Cz and the other electrode (cathode) over the right supraorbital region. For DLPFC, electrodes will be placed over F3 (anode) and F4 (cathode). Current intensity will be ramp up for 30 seconds until reaches 2 mA, and after 30 seconds current intensity will be ramp down for 15 seconds.</description>
    <arm_group_label>tDCS- SHAM</arm_group_label>
    <other_name>Sham TDCS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  suspected or confirmed diagnosis for SARS-CoV-2;&#xD;
&#xD;
          -  ability to understand and execute the proposed protocol;&#xD;
&#xD;
          -  vital signs (body temperature &lt;38ºC, blood pressure between 90 x 60mmHg and 140 x 90&#xD;
             mmHg, respiratory rate between 12 e 30 bpm).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  dyspnea or signs of respiratory effort;&#xD;
&#xD;
          -  SpO2 ≤ 90%;&#xD;
&#xD;
          -  hemodynamic instability;&#xD;
&#xD;
          -  deep vein thrombosis, active bleeding, use of cardiac pacemaker;&#xD;
&#xD;
          -  injury, pain or metallic implants in the cranium or scalp;&#xD;
&#xD;
          -  seizure history;&#xD;
&#xD;
          -  suspected or confirmed pregnancy;&#xD;
&#xD;
          -  concomitant or previous rheumatic or neurological diseases;&#xD;
&#xD;
          -  severe psychiatric diseases (schizophrenia, bipolar disorder, intellectual&#xD;
             disability);&#xD;
&#xD;
          -  severe musculoskeletal and/or integumentary disorders;&#xD;
&#xD;
          -  severe psychiatric disorders;&#xD;
&#xD;
          -  severe liver or kidney disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernanda F Tovar-Moll, PhD</last_name>
    <role>Study Director</role>
    <affiliation>D'Or Institute for Research and Education (IDOR)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erika C Rodrigues, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>D'Or Institute for Research and Education (IDOR)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erika C Rodrigues, PhD</last_name>
    <phone>+552138836000</phone>
    <email>erika.rodrigues@idor.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>D'Or Institute for Research and Education (IDOR)</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22.281-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>transcranial direct current stimulation (tDCS)</keyword>
  <keyword>executive function</keyword>
  <keyword>depression</keyword>
  <keyword>anxiety</keyword>
  <keyword>autonomic nervous system</keyword>
  <keyword>motor function</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

